|
시장보고서
상품코드
2089098
화이트 바이오테크놀러지 시장 : 제품 유형별, 원료별, 생물 유형별, 제품 형태별, 기술별, 생산 규모별, 최종 용도별 시장 예측(2026-2032년)White Biotechnology Market by Product Type, Feedstock Source, Organism Type, Product Form, Technology, Production Scale, End-Use - Global Forecast 2026-2032 |
||||||
360iResearch
화이트 바이오테크놀러지 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.51%로 성장이 전망되며, 5,673억 6,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 3,202억 2,000만 달러 |
| 추정 연도 : 2026년 | 3,467억 3,000만 달러 |
| 예측 연도 : 2032년 | 5,673억 6,000만 달러 |
| CAGR(%) | 8.51% |
화이트 바이오테크놀러지(산업 바이오테크놀러지라고도 함)는 효소, 미생물, 발효, 생체 촉매를 활용하여 화석 자원에 대한 의존도를 낮추면서 화학제품, 소재, 연료, 식품 원료, 산업용 원료를 제조하는 기술입니다. 제조업체들이 바이오 화학제품, 바이오플라스틱, 특수 효소, 지속 가능한 항공 연료의 중간체, 순환형 소재에 대한 확장 가능한 제조 경로를 모색함에 따라 그 중요성은 더욱 커지고 있습니다.
화이트 바이오테크놀러지 부문은 고립된 발효 자산에서 통합형 바이오 제조 플랫폼으로 전환되고 있습니다. 각 조직은 균주 공학, 정밀 발효, 연속 처리, 고도 정제, 공정 분석 기술을 결합하여 수율 향상, 폐기물 감축, 상용화 기간 단축을 도모하고 있습니다.
인공지능(AI)은 산업용 바이오기술의 누적적인 원동력이 되고 있습니다. AI를 활용한 단백질 설계, 대사 경로 모델링, 자동화된 균주 선정, 고성능 데이터 분석을 통해 연구자들은 기존의 시행착오 방식보다 더 신속하게 효소 후보 및 미생물 숙주를 식별할 수 있게 되었습니다.
아시아태평양은 대규모 제조 거점, 확대되는 바이오 경제 정책, 포장, 섬유, 식품 원료, 화학 분야에서 바이오 소재에 대한 활발한 수요를 배경으로 성장세를 보이고 있습니다. 중국, 인도, 일본, 한국, 호주, 아세안(ASEAN)은 발효 능력, 바이오매스 활용, 합성생물학 연구, 저탄소 제조 이니셔티브를 통해 산업 생명공학의 역량을 강화하고 있습니다. 북미는 확립된 생명공학 클러스터, 벤처 자금, 농업 원료의 가용성, 국가 차원의 바이오경제 전략, 국내 바이오 제조에 대한 연방 정부의 지원과 같은 강점을 활용하고 있으며, 재생 가능 화학물질, 지속 가능한 항공 연료로의 전환, 탄탄한 공급망에 대한 수요가 그 확산을 뒷받침하고 있습니다.
아세안(ASEAN) 시장은 농업 원료, 수출 지향적 생산, 포장 수요 증가, 식품 가공 산업의 성장에 힘입어 바이오 제조에 있어 점점 더 매력적인 시장이 되고 있습니다. GCC는 생명공학을 다각화 전략과 연계하고, 자본 조달 가능성, 에너지 인프라, 산업 단지, 신흥 순환형 탄소 이니셔티브를 활용하여 화학, 연료, 환경 용도 부문에서 산업 생명공학의 기회를 평가했습니다.
미국은 합성생물학, 벤처 자본을 통한 발효 플랫폼, 첨단 바이오 제조 정책, 농업 원료 통합 분야에서 선도적인 입지를 차지하고 있습니다. 한편, 캐나다는 바이오매스 자원, 청정 기술 프로그램, 강력한 연구 기관을 결합하고 있습니다. 멕시코는 북미 공급망과 연계된 바이오 투입 자재의 니어쇼어링 거점으로서의 입지를 확립하고 있으며, 브라질은 사탕수수, 에탄올에 대한 전문 지식, 임업 자원, 바이오매스의 가용성을 바탕으로 바이오 경제 분야의 주요 시장 진출기업으로 자리매김하고 있습니다.
산업 리더는 화이트 바이오테크놀러지이 기존의 석유화학 경로에 비해 성능, 비용, 공급 안정성 또는 탄소 배출량 측면에서 측정 가능한 우위를 제공하는 제품을 우선시해야 합니다. 대상 범주에는 특수 효소, 바이오 유래 중간체, 생분해성 폴리머, 식품 원료, 화장품 원료, 바이오 계면활성제, 명확한 인수 수요가 있는 저탄소 산업용 화학물질 등이 포함됩니다.
본 요약 보고서는 2차 조사, 규제 검토, 기술 매핑, 특허 및 과학 문헌 평가, 산업 수준 분석을 결합한 체계적인 조사 접근 방식을 기반으로 합니다. 검토 대상 정보원에는 공공 정책 문서, 정부의 바이오경제 전략, 산업 단체 자료, 기업 공시 정보, 동료 심사 저널, 규격 지침, 산업 바이오기술 참여 기업들의 상업화 관련 최신 정보 등이 포함됩니다.
화이트 바이오테크놀러지는 지속가능성을 추구하는 틈새 시장에서 화학물질, 소재, 연료, 식품 원료, 소비재용 전략적 제조 플랫폼으로 전환되고 있습니다. 그 장기적인 경쟁력은 수율 향상, 원료의 유연성, 비용 효율적인 규모 확대, 규제 명확화, 투명성이 높은 라이프사이클 데이터에 뒷받침된 신뢰할 수 있는 탄소 성과에 달려 있습니다.
The White Biotechnology Market is projected to grow by USD 567.36 billion at a CAGR of 8.51% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 320.22 billion |
| Estimated Year [2026] | USD 346.73 billion |
| Forecast Year [2032] | USD 567.36 billion |
| CAGR (%) | 8.51% |
White biotechnology, also called industrial biotechnology, applies enzymes, microorganisms, fermentation, and biocatalysis to manufacture chemicals, materials, fuels, food ingredients, and industrial inputs with lower dependence on fossil resources. Its relevance is rising as manufacturers seek scalable routes to bio-based chemicals, bioplastics, specialty enzymes, sustainable aviation fuel intermediates, and circular materials.
The sector is supported by proven scientific foundations in metabolic engineering, synthetic biology, feedstock conversion, and downstream processing. Adoption is strongest where sustainability targets, resilient supply chains, renewable carbon use, and life-cycle greenhouse gas reduction are becoming procurement requirements rather than optional brand claims.
The white biotechnology landscape is shifting from isolated fermentation assets toward integrated biomanufacturing platforms. Organizations are combining strain engineering, precision fermentation, continuous processing, advanced purification, and process analytical technologies to improve yield, reduce waste, and shorten commercialization timelines.
Feedstock strategy is also changing. Beyond sugar and starch streams, innovators are evaluating lignocellulosic biomass, agricultural residues, municipal waste, captured carbon, and industrial off-gases. This shift is reshaping cost structures, strengthening circular economy models, and encouraging partnerships across agriculture, chemicals, energy, packaging, textiles, food, and consumer goods.
Artificial intelligence is becoming a cumulative accelerator for industrial biotechnology. AI-enabled protein design, pathway modeling, automated strain selection, and high-throughput data analysis help researchers identify enzyme candidates and microbial hosts faster than traditional trial-and-error approaches.
At commercial scale, machine learning supports fermentation control, contamination detection, predictive maintenance, and digital twins for bioreactors. The highest value comes when AI is linked to validated laboratory data, robust process analytics, and disciplined governance, because model quality directly depends on experimental reliability, data provenance, and traceable datasets.
Asia-Pacific is gaining momentum through large manufacturing bases, expanding bioeconomy policies, and strong demand for bio-based materials in packaging, textiles, food ingredients, and chemicals. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening industrial biotechnology capabilities through fermentation capacity, biomass utilization, synthetic biology research, and low-carbon manufacturing initiatives. North America benefits from established biotechnology clusters, venture funding, agricultural feedstock availability, national bioeconomy strategies, and federal support for domestic biomanufacturing, with adoption supported by demand for renewable chemicals, sustainable aviation fuel pathways, and resilient supply chains.
Europe remains a policy-led region where circular economy rules, industrial decarbonization, renewable materials procurement, and green chemistry priorities support white biotechnology adoption. Latin America has strategic advantages in biomass, sugarcane, forestry resources, and biofuels experience, with Brazil and Mexico acting as important anchors for bio-based production and regional value chains. The Middle East is exploring biotechnology as part of industrial diversification, circular carbon management, and downstream chemical innovation, while Africa offers long-term potential through agricultural residues, local fermentation capacity, food security needs, and demand for sustainable industrialization.
ASEAN markets are increasingly attractive for bio-based manufacturing because of agricultural feedstocks, export-oriented production, growing packaging demand, and expanding food-processing industries. The GCC is aligning biotechnology with diversification strategies, using capital availability, energy infrastructure, industrial zones, and emerging circular carbon initiatives to evaluate industrial biotech opportunities in chemicals, fuels, and environmental applications.
The European Union provides one of the most structured regulatory and funding environments for bio-based products, particularly through climate policy, circular economy action, sustainable product rules, and green chemistry priorities. BRICS economies bring scale, biomass availability, manufacturing depth, and large domestic end-use demand, while the G7 leads in R&D intensity, intellectual property creation, quality systems, and advanced biomanufacturing standards. NATO countries add strategic relevance as governments increasingly view biotechnology capacity, bio-based inputs, and domestic production networks as part of supply chain resilience and industrial security.
The United States leads in synthetic biology, venture-backed fermentation platforms, advanced biomanufacturing policy, and agricultural feedstock integration, while Canada combines biomass resources, clean technology programs, and strong research institutions. Mexico is positioned as a nearshoring hub for bio-based inputs linked to North American supply chains, and Brazil is a major bioeconomy player due to sugarcane, ethanol expertise, forestry resources, and biomass availability.
In Europe, the United Kingdom emphasizes life sciences commercialization and engineering biology, Germany anchors industrial enzymes, specialty chemicals, and process engineering, France supports bio-based materials and agriculture-linked innovation, Italy and Spain benefit from circular economy programs, food-processing ecosystems, and biorefinery opportunities, and Russia has feedstock depth but faces investment, technology access, and trade constraints. In Asia-Pacific, China scales biomanufacturing capacity and synthetic biology applications, India offers cost-efficient fermentation, agricultural residues, and pharmaceutical biotechnology capabilities, Japan focuses on high-value bio-based materials and precision process quality, Australia supports biomass and clean technology pathways, and South Korea advances precision fermentation, biotechnology-enabled materials, and high-tech manufacturing integration.
Industry leaders should prioritize products where white biotechnology offers measurable performance, cost, supply security, or carbon advantages over incumbent petrochemical routes. Target categories include specialty enzymes, bio-based intermediates, biodegradable polymers, food ingredients, cosmetics inputs, biosurfactants, and low-carbon industrial chemicals with clear offtake demand.
Executives should build feedstock resilience, validate life-cycle assessments early, and secure partnerships with agriculture, waste management, chemical producers, downstream buyers, logistics providers, and contract biomanufacturers. AI investments should be tied to data governance, laboratory automation, and process analytics, while regulatory, labeling, certification, and end-of-life requirements must be addressed before scale-up to reduce commercialization risk.
This executive summary is grounded in a structured research approach combining secondary research, regulatory review, technology mapping, patent and scientific literature assessment, and industry-level analysis. Sources considered include public policy documents, government bioeconomy strategies, industry association materials, corporate disclosures, peer-reviewed publications, standards guidance, and commercialization updates from industrial biotechnology participants.
Insights were triangulated across technology readiness, feedstock availability, regional policy signals, end-use adoption, sustainability criteria, and competitive activity. The methodology emphasizes verified evidence, consistency across independent sources, life-cycle relevance, and practical value for decision-makers evaluating the white biotechnology market and adjacent bioeconomy opportunities.
White biotechnology is moving from a sustainability niche into a strategic manufacturing platform for chemicals, materials, fuels, food ingredients, and consumer products. Its long-term competitiveness will depend on yield improvement, feedstock flexibility, cost-efficient scale-up, regulatory clarity, and credible carbon performance supported by transparent life-cycle data.
Organizations that combine synthetic biology, AI-enabled optimization, circular feedstocks, and strong commercialization partnerships will be best positioned to capture opportunities in the global bioeconomy. As policy, procurement, and consumer expectations continue to favor low-carbon production, industrial biotechnology is set to play a larger role in sustainable manufacturing and resource-efficient value chains.